Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis.
作者: Su QiangZhang Xiao-ChenZhang Chen-GuangHou Yan-LiYao Yu-XiaCao Bang-Wei
作者单位: 1Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
2Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing 100084, China.
3Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.
4Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
5Department of Digestive Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
刊名: Journal of immunology research, 2018, Vol.2018 , pp.1027323
来源数据库: PubMed Journal
DOI: 10.1155/2018/1027323
原始语种摘要: We performed a systematic review and meta-analysis to determine the risk of immune-related pancreatitis associated with the treatment by immune checkpoint inhibitors (ICIs) for solid tumors. Eligible studies were selected from multiple databases including phase II/III randomized controlled trials (RCTs) with ICIs in solid tumor patients. The data were analyzed with Stata version 12.0 software. After excluding ineligible studies, a total of 15 clinical trials were considered eligible for the meta-analysis, which included 9099 patients. Compared with chemotherapy or placebo, the risk ratio (RR) for all-grade lipase elevation after CTLA-4 inhibitor treatment was 1.05 (95% confidence interval (CI): 1.01-2.24, p = 0.047). However, the risk for pancreatitis after ICI treatment in any subgroup...
全文获取路径: PubMed  (合作)

  • treatment 处理
  • increase 增加
  • pancreatitis 胰脏炎
  • ineligible 不合格的
  • interval 区间
  • higher 
  • ratio 
  • elevation 隆起
  • grade 品位
  • analysis 分析